MktsMarkets

C4 Therapeutics, Inc.
NASDAQ: CCCCKey statistics
CCCC News
Stories mentioning CCCC from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 6,152 | 11,016 | 11,230 | 6,463 | 7,238 | 5,177 | 15,362 | 12,006 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 24,606 | 24,982 | 25,989 | 26,197 | 27,072 | 32,513 | 31,838 | 23,753 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 33,937 | 34,161 | 45,642 | 34,964 | 36,402 | 42,886 | 43,606 | 33,448 |
| Operating Income (Loss) | (27,785) | (23,145) | (34,412) | (28,501) | (29,164) | (37,709) | (28,244) | (21,442) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (20,365) | (32,166) | (26,020) | (26,322) | (34,442) | (24,666) | (17,716) | |
| Tax Provision | 0.00 | 0.00 | 0.00 | 131.00 | 0.00 | 0.00 | ||
| Net Income (Loss) | (25,129) | (20,486) | (32,166) | (26,020) | (26,322) | (34,573) | (24,666) | (17,716) |
| Earnings Per Share (Basic) | (0.20) | (0.25) | (0.44) | (0.37) | (0.37) | (0.50) | (0.35) | (0.26) |
| Earnings Per Share (Diluted) | (0.20) | (0.25) | (0.44) | (0.37) | (0.37) | (0.50) | (0.35) | (0.26) |
| Weighted Average Shares Outstanding (Basic) | 126,075 | 82,894 | 72,563 | 71,006 | 70,833 | 69,373 | 69,627 | 68,810 |
| Weighted Average Shares Outstanding (Diluted) | 126,075 | 82,894 | 72,563 | 71,006 | 70,833 | 69,373 | 69,627 | 68,810 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About CCCC
C4 Therapeutics, Inc. (NASDAQ: CCCC) is a stock listed on the Nasdaq Stock Market under the ticker symbol CCCC. It last traded at $2.49 (Nov 19, 2026, 2:46 PM ET), up 0.6% on the day. That gives C4 Therapeutics a market capitalisation of $330.3M.
Over the past 52 weeks CCCC has traded between $1.69 and $5.17.
Revenue for the quarter ended Mar 31, 2026 was $6.2M; a net loss of $25.1M. Revenue was down 15.0% from $7.2M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $6.2M | -$25.1M | -408.5% |
| Dec 31, 2025 | $11.0M | -$20.5M | -186.0% |
| Sep 30, 2025 | $11.2M | -$32.2M | -286.4% |
| Jun 30, 2025 | $6.5M | -$26.0M | -402.6% |
From C4 Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…